Literature DB >> 25908032

Risk patterns of subsequent primary cancers following esophagectomy in early-stage thoracic esophageal squamous cell cancer patients.

Wen-Si Hu1, Zeng-Jun Liu, Jian-Bo Zhang, Zeng-Liang Wang, Ning Yang, Liang Xu, Hui Tian, Pin-Liang Zhang.   

Abstract

AIMS AND
BACKGROUND: Subsequent primary cancers (SPCs) have been demonstrated to be the major causes of death among patients with thoracic esophageal squamous cell cancer (ESCC) negative for lymph node involvement. We designed this study to investigate clinical characteristics and risk patterns of SPCs following esophagectomy in patients with early-stage thoracic ESCC.
METHODS: We retrospectively analyzed clinical factors in 512 patients with early-stage thoracic ESCC collected from 3 independent hospitals over a 10-year interval.
RESULTS: The overall standard incidence rate (SIR) of SPCs was 3.84 (95% confidence interval 2.98-4.95). The most common SPCs were head and neck cancers, lung cancer, and stomach cancer. The risk patterns of SPCs varied across organs. A 3-phase risk pattern with a U-shaped curve between 2 rising phases was seen for head and neck cancers, while for the other cancers, the risk patterns all displayed as an approximately linear upward trend. It was further noted that sex, smoking habits, and cancer histories among first-degree relatives were 3 significant independent risk factors in the development of SPCs.
CONCLUSIONS: We observed significant associations between early-stage ESCC and SPCs arising from anatomically adjacent sites. The different risk patterns of SPCs indicated that follow-up strategies should be established accordingly in different organs at different times, with particularly close follow-up for head and neck cancers in the first 5 years and beyond 15 years after diagnosis of ESCC.

Entities:  

Mesh:

Year:  2015        PMID: 25908032     DOI: 10.5301/tj.5000285

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  5 in total

1.  Prevalence of lung tumors in patients with esophageal squamous cell carcinoma and vice versa: a systematic review and meta-analysis.

Authors:  Laurelle van Tilburg; Steffi E M van de Ven; Manon C W Spaander; Laurens A van Kleef; Robin Cornelissen; Marco J Bruno; Arjun D Koch
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-23       Impact factor: 4.553

2.  Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: supplementary analysis of the JCOG trial: JCOG0502.

Authors:  Seiichiro Mitani; Ken Kato; Hiroyuki Daiko; Yoshinori Ito; Isao Nozaki; Takashi Kojima; Masahiko Yano; Satoru Nakagawa; Masaki Ueno; Masaya Watanabe; Shigeru Tsunoda; Tetsuya Abe; Shigenori Kadowaki; Tomohiro Kadota; Keita Sasaki; Ryunosuke Machida; Yuko Kitagawa
Journal:  J Gastroenterol       Date:  2022-05-11       Impact factor: 6.772

3.  Increased risk of second primary tumours in patients with oesophageal squamous cell carcinoma: a nationwide study in a Western population.

Authors:  Steffi E M van de Ven; Janne M Falger; Rob H A Verhoeven; Robert J Baatenburg de Jong; Manon C W Spaander; Marco J Bruno; Arjun D Koch
Journal:  United European Gastroenterol J       Date:  2021-03-29       Impact factor: 4.623

4.  A nomogram for endoscopic screening in a high esophageal squamous cell cancer risk area: results from a population-based study.

Authors:  Jie Xing; Li Min; Hao Zhang; Peng Li; Wei Li; Fujin Lv; Yongjun Wang; Zheng Zhang; Hengcun Li; Qingdong Guo; Siyi Wang; Yu Zhao; Junmin Wang; Xiaoyan Shi; Anxin Wang; Shengtao Zhu; Ming Ji; Yongdong Wu; Shutian Zhang
Journal:  Cancer Manag Res       Date:  2019-01-03       Impact factor: 3.989

5.  Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis.

Authors:  Seiichiro Mitani; Shigenori Kadowaki; Isao Oze; Toshiki Masuishi; Yukiya Narita; Hideaki Bando; Sachiyo Oonishi; Yutaka Hirayama; Tsutomu Tanaka; Masahiro Tajika; Yutaro Koide; Takeshi Kodaira; Tetsuya Abe; Kei Muro
Journal:  Cancer Med       Date:  2019-11-15       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.